Dysregulation of miR-210 is involved in the development of diabetic retinopathy and serves a regulatory role in retinal vascular endothelial cell proliferation

Chengyu Yin*, Xiangqiang Lin, Yafei Sun and Xinli Ji

Abstract
Background: Diabetic retinopathy is a common complication of diabetes mellitus (DM). The purpose of this study was to investigate the expression and clinical significance of miR-210 in DR patients and explore the regulatory effect of miR-210 on vascular endothelial cell function under high-glucose condition.

Methods: Quantitative real-time PCR was used to estimate miR-210 expression. A receiver operating characteristics curve (ROC) was plotted to evaluate the diagnostic value of miR-210. Human umbilical vein endothelial cells (HUVECs) were used and treated with high glucose (30 mM), and the cell proliferation was assessed by MTT assay.

Results: Serum expression of miR-210 was upregulated in DR patients compared with DM without DR patients and healthy controls. The expression of miR-210 in proliferative DR (PDR) patients was higher than non-proliferative DR (NPDR) patients. The increased serum miR-210 could be used to distinguish DR cases from healthy individuals and also simple DM patients, and can screen PDR cases from NPDR cases. The overexpression of miR-210 promoted HUVEC proliferation, while the knockdown of miR-210 resulted in the opposite effect under a high-glucose condition.

Conclusion: The data of this study demonstrated that serum increased miR-210 serves as a diagnostic biomarker in DR patients and may have the ability to predict DR development and severity. The regulatory effect of miR-210 on vascular endothelial cell proliferation under high-glucose condition, indicating its therapeutic potential in the treatment of diabetic vascular diseases.

Keywords: Diabetic retinopathy, MicroRNA-210, Diabetes mellitus, Diagnosis, Vascular endothelial cell, Proliferation
to advanced DR and are defined as proliferative DR (PDR) [6]. Thus, the identification of molecules involving the regulation of vascular endothelial cell function and angiogenesis may help to improve the treatment of DR.

Abnormal microRNAs (miRNAs) have been identified in various human diseases with an important functional role in disease pathogenesis [7]. Numerous miRNAs have been demonstrated to be involved in the progression of DM, as well as various complications of DM, including DR [8, 9]. For example, miR-21 has been determined as a novel therapeutic target of DR by regulating retinal neovascularization and inflammation [10]. The knockdown of miR-218 might be a promising therapeutic approach of DR by promoting retinal pigment epithelium proliferation and inhibiting cell apoptosis [11]. Dysregulation of miR-210 is involved in the progression of DM [12], and its promoting effect on angiogenesis by increasing vascular endothelial cell proliferation has also been reported in several previous studies [13, 14]. However, the expression data of miR-210 in DR has not been investigated.

Considering the reported important role of miR-210 in DM and endothelial cell function, this study aimed to assess the expression patterns of miR-210 in DR patients, as well as its clinical significance in diagnosis and severity prediction. Furthermore, this study also investigated the regulatory effect of miR-210 on the cell proliferation of HUVECs upon high-glucose condition.

**Materials and methods**

**Patients and clinical samples collection**

This study was performed with the approval by the Ethics Committee of Qingdao Chengyang People’s Hospital, and all participants wrote the informed consent before sampling. A total of 150 type 2 DM patients and 60 age- and gender-matched healthy volunteers were recruited in this study from Qingdao Chengyang People’s Hospital between 2015 and 2017. The demographic characteristics of the two groups are recorded in Table 1. Exclusion criteria were as follows: patients accompanied by diabetic ketoacidosis, diabetic hyperosmolar coma and other acute complications of diabetes; patients having a history of myocardial infarction, coronary artery bypass surgery; patients with liver or renal dysfunction; patients suffering from peripheral vascular diseases and other endocrine and metabolic diseases; patients with cancer. All the participants received an ophthalmologic examination. The DM patients were diagnosed in line with the American Diabetes Association criteria [15] and divided into three groups, including 40 DM without DR patients (NDR group), 60 NPDR patients (NPDR group) and 50 PDR patients (PDR group), based on the fundus fluorescence angiography (FFA) results. The diagnosis of DR was determined by two experienced physicians following the designated staging criteria in the fundi disease academic conference [16]. The demographic and clinical data of the study population are recorded in Table 2.

Blood samples were collected from the participants, and serum samples were isolated from the blood by centrifugation and stored at −80 °C for further analysis. The clinical characteristics of the patients, including disease course, fasting plasma glucose (FPG), triglyceride (TG), total cholesterol (TC), glycosylated hemoglobin (HbA1c), fasting insulin (FINS) and the calculated Homoeostasis model assessment of insulin resistance (HOMA-IR), were recorded for further analysis.

**Cell culture and treatment**

Human umbilical vein endothelial cells (HUVECs) were purchased from the Cell Bank in the Shanghai Institute for Biological Sciences of the Chinese Academy of Sciences (Shanghai, China) and cultured in RPMI-1640 medium (Gibco, Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Sigma-Aldrich, Merck KGaA, Germany) at 37 °C in a humidified incubator with 5% CO₂. To obtain HUVECs under hyperglycemia condition, HUVECs were subjected to 30 mM glucose (HG group) as the previous study reported [17]. Besides, a glucose control group was performed by treating the cells with 5 mM glucose (LG group).

**Cell transfection**

To regulate the expression of miR-210 in HUVECs, miR-210 mimic, miR-210 inhibitor and the negative controls (mimic NC and inhibitor NC) were separately transfected into the cells by Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instruction. After 24 h of transfection, cells were received glucose treatment.

**RNA extraction and quantitative real-time PCR (qRT-PCR)**

Total RNA in serum and cells was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and then
Table 2  Comparison of the demographic and clinical data of patients in each group

| Group | Age (year) | Gender (male/female) | BMI (kg/m²) | Disease course (year) | FPG (mmol/l) | TG (mmol/l) | TC (mmol/l) | HbA1c (%) | FINS (mIU/l) | HOMA-IR |
|-------|------------|----------------------|-------------|-----------------------|--------------|-------------|-------------|-----------|--------------|---------|
| HC    | 50.85 ± 5.20 | 28/32 | 21.81 ± 2.20 | - | 5.14 ± 0.83 | 1.47 ± 0.17 | 4.28 ± 0.49 | 4.92 ± 0.46 | 5.38 ± 0.54 | 1.29 ± 0.08 |
| NDR   | 50.23 ± 3.81 | 23/17 | 21.78 ± 1.84 | 4.27 ± 0.72 | 6.15 ± 0.58* | 1.50 ± 0.14 | 4.40 ± 0.51 | 6.61 ± 0.59* | 5.41 ± 0.65 | 1.57 ± 0.10* |
| NPDR  | 50.73 ± 3.80 | 28/32 | 22.07 ± 2.73 | 9.55 ± 1.57*# | 7.42 ± 0.31*# | 1.52 ± 0.28 | 4.50 ± 0.75 | 7.31 ± 0.28*# | 5.46 ± 0.79 | 1.61 ± 0.28* |
| PDR   | 51.40 ± 3.93 | 26/24 | 22.61 ± 3.12 | 12.68 ± 1.43*# | 8.51 ± 0.44*# | 1.55 ± 0.26 | 4.57 ± 0.73 | 8.00 ± 0.34*# | 5.51 ± 0.63 | 1.84 ± 0.23*# |

Data are expressed as the mean ± SD or number. Multiple comparisons were made using ANOVA followed by Tamhane’s T2 tests, while the gender distribution among groups were evaluated by using Chi-square test.

HC healthy control, NDR DM without DR patients, NPDR non-proliferative DR, PDR proliferative DR, FPG fasting plasma glucose, TG triacylglycerol, TC total cholesterol, HbA1c glycosylated hemoglobin, FINS fasting insulin, HOMA-IR homoeostasis model assessment of insulin resistance.

*P < 0.05 compared with HC group; #P < 0.05 compared with NDR group; †P < 0.05 compared with NPDR group.
reversed transcribed into cDNA by a PrimeScript RT reagent kit (TaKaRa, Shiga, Japan) based on the manufacturer’s protocol. The following qPCR was performed using a 7300 Real-Time PCR System (Applied Biosystems, USA) and the SYBR green I Master Mix kit (Invitrogen, Carlsbad, CA, USA). The relative expression of miR-210 was calculated using $2^{-\Delta\Delta Ct}$, and U6 was used as the internal control for miRNA quantification.

**MTT assay**

HUVECs were seeded into 96-well plates with a cell density of $5 \times 10^3$ cell/well and cultured at 37 °C for 78 h. At the culture time points of 0, 24, 48 and 72 h, 10 μL MTT solution (25 mg/mL; Sigma-Aldrich, Merck KGaA, Germany) was added to the cells with further 4 h of incubation. After removing the medium, 150 μL DMSO (Sigma-Aldrich) was added to each well with 10 min of incubation. The absorbance of the cell culture at 490 nm was read using a microplate reader (BIO-RAD, Hercules, CA, USA). The experiments were repeated 3 times.

**Statistical analysis**

All data obtained from this study were presented as mean ± SD and analyzed using SPSS 21.0 software (SPSS Inc., Chicago, IL) and GraphPad Prism 7.0 software (GraphPad Software, Inc., USA). Differences between groups were analyzed using Student’s t test, Chi-square test, and one-way ANOVA followed by Tukey’s or Tamhane’s T2 tests. As each variable approximated the normal distribution according to the Kolmogorov–Smirnov (K-S) normality test results, correlation analysis was performed using Pearson correlation analysis. A receiver operating characteristics curve (ROC) analysis was performed to evaluate the diagnostic value of miR-210. A P value of less than 0.05 indicated statistically significant.

**Results**

**Comparison of the demographic and clinical data of patients in each group**

The demographic and clinical data of the study population are recorded in Table 2. It was found that there was no significant difference for age, gender, BMI, TG, TC and FINS among different groups (all $P>0.05$). Compared with the HC group, the levels of FPG, HbA1c, and HOMA-IR were significantly increased in the NDR, NPDR, and PDR groups, and show a gradually increasing trend from the NDR group to the NPDR group to the PDR group. Additionally, the levels of disease course, FPG and HbA1c were significantly higher in both NPDR, and PDR groups than that in NDR group (all $P<0.05$).

**Expression of miR-210 in the study population**

According to qRT-PCR, we found that serum expression of miR-210 was upregulated in DM patients, including NDR and DR patients, when compared to the healthy controls (all $P<0.05$, Fig. 1). The expression levels of miR-210 in both the NPDR and PDR groups were increased compared with the NDR group (both $P<0.05$). Of note, a significant difference in miR-210 expression was also found between the NPDR and PDR patients, which showed the higher miR-210 expression in the PDR group relative to the NPDR group ($P<0.05$).

**Correlation between miR-210 and clinical characteristics of DR patients**

Pearson correlation analysis results listed in Table 3 show that miR-210 expression was positively correlated with disease course ($r=0.835$, $P<0.001$), FPG ($r=0.798$, $P<0.001$), HbA1C ($r=0.862$, $P<0.001$) and HOMA-IR ($r=0.680$, $P<0.001$). No significant correlation was found between miR-210 and TG, TC, and FINS (all $P>0.05$).

**Diagnostic performance of miR-210 in DR patients**

Given the dysregulation of miR-210, this study further evaluated the diagnostic value of miR-210 in the distinguishing patients in different groups using the ROC analysis. As shown in Fig. 2a, serum miR-210 expression could be used to differentiate DR patients from healthy controls with an area under the curve (AUC) of 0.991. The sensitivity and specificity were 95.5% and 95.0%, respectively, at a cutoff value of 1.905. Furthermore, a ROC curve for the differentiation between DR
and DM patients without DR showed an AUC of 0.892, a sensitivity of 83.6% and a specificity of 80.0% at a cutoff value of 2.335 (Fig. 2b), indicating that serum miR-210 expression had a relatively high predictive value for DR in DM patients. More important, a ROC curve constructed based on serum miR-210 expression in NPDR and PDR patients yields an AUC of 0.810, with a sensitivity of 82.0% and specificity of 75.0%, and the optimal cutoff value was 3.070 (Fig. 2c), indicating the diagnostic value of miR-210 in distinguishing NPDR and PDR cases.

Expression of miR-210 in glucose-treated HUVECs
The expression of miR-210 in HUVECs treated with high glucose (30 mM) was significantly increased compared with the cells in the normal control group (5 mM glucose) (P < 0.05, Fig. 3), which was consistent with the expression tendency of serum miR-210 in DR patients.

Effect of miR-210 on HUVEC proliferation
By in vitro manipulation of miR-210, the expression of miR-210 in high glucose-treated HUVECs was upregulated by the miR-210 mimic and was downregulated by the miR-210 inhibitor (all P < 0.05, Fig. 4a). The subsequent MTT assay results shown in Fig. 4b showed that the high glucose led to inhibited HUVEC proliferation, and this effect was ameliorated by the overexpression of miR-210, while it was aggravated by the knockdown of miR-210 (all P < 0.05).

Discussion
DM is a common and complex metabolic disorder disease with increasing morbidity worldwide. Long-term hyperglycemia promotes vascular injury, leading to various complications, including DR, diabetic nephropathy, diabetic cataract, diabetic foot, diabetic cardiovascular diseases and diabetic cerebrovascular diseases [18]. A large number of miRNAs have been investigated in DM patients and act as functional roles in DM progression [19, 20]. Furthermore, some miRNAs have also been found to regulate the development of diabetic complications, such as miR-126, miR-23b, and miR-122. Notably, the upregulated expression of miR-210 has been reported

| Indicators       | MiR-210 | R     | P     |
|------------------|---------|-------|-------|
| Disease course   | 0.835   | <0.001*|
| FPG              | 0.798   | <0.001*|
| TG               | 0.012   | 0.203 |
| TC               | 0.050   | 0.307 |
| HbA1c            | 0.862   | <0.001*|
| FINS             | 0.033   | 0.434 |
| HOMA-IR          | 0.680   | <0.001*|

FPG fasting plasma glucose, TG triacylglycerol, TC total cholesterol, HbA1c glycosylated hemoglobin, FINS fasting insulin, HOMA-IR homeostasis model assessment of insulin resistance

*P < 0.05
in DM patients, and is involved in the progression of DM-associated with coronary artery diseases [21]. The dysregulation of miR-210 has also been suggested to participate in the regulation of diabetes on angiogenesis by regulating endothelial dysfunction in the development of DM-related cardiovascular diseases [12]. In the present study, a total of 150 type 2 DM patients were recruited to explore the expression changes of miR-210. It was noted that the serum miR-210 level was increased in DM patients compared with healthy controls, which was consistent with the previous evidence [21]. Additionally, the enrolled DM patients in the current study were further divided into NDR group, NPDR group and PDR group, and the results indicated that serum miR-210 expression in DR patients was increased compared with DM patients without DR, revealing that miR-210 might also play a role in the development of DR in DM patients.

To understand the mechanism of miR-210 in the development of DM with DR, the relationship between miR-210 and clinical characteristics of DR patients was investigated. Our correlation analysis results revealed that miR-210 expression was positively correlated with disease course, FPG, HbA1c and HOMA-IR. In American Diabetes Association criteria, an FPG of 7.0 mM is a threshold to define the presence of diabetes, which is correlated with the onset of DR [22]. The increased variability of HbA1c is considered to be one of the risk factors of DR [23]. The value of HbA1c needed to be monitored for patients receiving intensive insulin treatment, and is considered as a diagnostic biomarker for DM-associated complications [24]. HOMA-IR is used for the assessment of insulin resistance, the increased HOMA-IR has a strong impact on insulin secretion and the progression of DM [25]. According to the clinical characteristics of DR patients, a close association was detected for serum miR-210 level with disease course, FPG, HbA1c, and HOMA-IR in DM patients. Considering the important role of these markers in reflecting the progression and complication of DM, we deduced that miR-210 might be associated with the development of DR.

Deregulated circulating miRNAs have been proposed as promising diagnostic tools for various human diseases [26]. In this study, increased expression of serum miR-210 was observed in DR patients than that in both DM without DR patients and healthy volunteers. According to the ROC analysis, this study found that using serum miR-210 could distinguish DR patients from healthy individuals, suggesting the
diagnostic value of miR-210 for DM. Additionally, considering the dysregulation of miR-210 between NDR and DR patients, we considered that miR-210 might serve as an indicator to predict the onset of DR in DM patients, which was supported by the ROC analysis results. Besides, higher miR-210 expression was found in PDR patients compared with NPDR patients. The subsequent ROC results showed that miR-210 had relative diagnostic accuracy in the distinguishing of PDR from NPDR, indicating that miR-210 could be used to screen PDR cases and might be related to DR severity. The dysfunction of retinal vascular endothelial cells represents a clinical manifestation of DR. This study used HUVECs to investigate the function of vascular endothelial cells under high-glucose condition. HUVECs have been commonly used in previous studies, including the studies regarding the endothelial cell function in DR [27]. The cell results found that high-glucose treatment led to increased expression of miR-210, which was consistent with the results observed in DM patients. Additionally, the gain and loss function experiments results indicated that over-expression of miR-210 promoted cell proliferation in HUVECs under high-glucose condition. Consistently, the promoting effect of miR-210 on angiogenesis by increasing vascular endothelial cell proliferation has also been reported in several previous studies [13, 14], which supported our present results. Retinal neovascularization is one of the characteristics of DR pathogenesis and involved in the development of PDR [25]. Thus, therapeutic methods involving the regulation of hyperglycemia-induced angiogenesis are developed for the prevention and treatment of DR [28]. A study by Naderi et al. has reported the regulatory role of miR-210 on angiogenesis in DM-related cardiovascular disease [21]. The demethylation of miR-210 could also promote angiogenesis in schwannoma cells under hypoxia [29]. The present results in combination with the regulatory effect of miR-210 on angiogenesis led us to suspect that miR-210 might be involved in the retinal neovascularization in DR pathogenesis. However, the effect of miR-210 on retinal vascular endothelial cell function was not investigated in this study, which may be a limitation of this study. To verify our hypothesis, further studies should focus on the functional role of miR-210 in the development of DM-related retinal endothelial cell injury. Additionally, it is reported that not all miRNAs detected in serum correlate with intra-vitreal level of the same miRNA in DR patients, but in the present study, only levels of miR-210 in the serum was detected [30]. Further studies are needed to detect the expression changes of miR-210 in the intravitreal of DR patients.

Conclusion

In conclusion, increased serum miR-210 in DR patients serves as a candidate diagnostic biomarker, which may be used to predict the development of DR in DM patients and associated with DR severity. Besides, miR-210 may be involved in the regulation of vascular endothelial cell proliferation under high-glucose condition, indicating its therapeutic potential in the treatment of diabetic vascular diseases.

Abbreviations

DM: Diabetes mellitus; ROC: Receiver operating characteristics curve; HUVECs: Human umbilical vein endothelial cells; PDR: Proliferative DR; NPDR: Non-proliferative DR; miRNAs: MicroRNAs; FFA: Fundus fluorescence angiography; FPG: Fasting plasma glucose; TG: Triacylglycerol; TC: Total cholesterol; HbA1c: Glycosylated hemoglobin; FINS: Fasting insulin; HOMA-IR: Homoeostasis model assessment of insulin resistance; HUVECs: Human umbilical vein endothelial cells; FBS: Fetal bovine serum; qRT-PCR: Quantitative real-time PCR; ROC: Receiver operating characteristics curve.

Acknowledgements

Not applicable.

Authors’ contributions

CY and XL initiated and designed the work. CY, YS, and XJ performed the experiments. CY was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

This study was performed with the approval by the Ethics Committee of Qingdao Chengyang People’s Hospital, and all participants wrote the informed consent before sampling.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 13 January 2020    Accepted: 21 May 2020
Published online: 29 May 2020

References

1. Heng LZ, Comyn O, Peto T, Tadros C, Ng E, Sivaprasad S, et al. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabet Med. 2013;30(6):640–50.
2. Moreno A, Lozano M, Salinas P. Diabetic retinopathy. Nutricion Hosp. 2013;2:53–6.
3. Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy: Indian J Ophthalmol. 2012;60(5):429–31.
4. Durham JT, Herman IM. Microvascular modifications in diabetic retinopathy. Curr Diabet Rep. 2011;11(4):253–64.
5. Shan K, Liu C, Liu BH, Chen X, Dong R, Liu X, et al. Circular noncoding RNA HIPK3 mediates retinal vascular dysfunction in diabetes mellitus. Circulation. 2017;136(17):1629–42.
6. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36.
7. Vienberg S, Geiger J, Madsen S, Dalgaard LT. MicroRNAs in metabolism. Acta Physiologica. 2017;219(2):346–61.
8. Gong Q, Su G. Roles of miRNAs and long noncoding RNAs in the progression of diabetic retinopathy. Biosci Rep. 2017;37(6):BSR20171157.
9. Sharma S, Mathew AB, Chugh J. miRNAs: nanomachines that micro-manage the pathophysiology of diabetes mellitus. Adv Clin Chem. 2017;82:199–264.
10. Chen Q, Qiu F, Zhou K, Matlock HG, Takahashi Y, Rajala RVS, et al. miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of type 2 diabetes mellitus. Exp Ther Med. 2017;14(6):5589–96.
11. Amir KS, Abdelmawgoud H, Ali ZY, Shehata S, Raslan HM. Potential value of circulating microRNA-126 and microRNA-210 as biomarkers for type 2 diabetes with coronary artery disease. Br J Biomed Sci. 2018;75(2):82–7.
12. Cheng YJ, Gregg EW, Geiss LS, Imperatore G, Williams DE, Zhang X, et al. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds. Diabet Care. 2009;32(11):2027–32.
13. Hermann JM, Hammes HP, Rami-Merhar B, Rosenbauer J, Schütt M, Siegel E, et al. HbA1c variability as an independent risk factor for diabetic retinopathy in type 1 diabetes: a German/Austrian multicenter analysis on 35,891 patients. PLoS ONE. 2014;9(3):e91137.
14. McCoy RG, Van Houten HK, Rios JS, Montori VM, Shah ND. HbA1c overtreatment and overtreatment among US adults with controlled type 2 diabetes, 2001–2013: observational population based study. BMJ. 2015;351:h6138.
15. Morimoto A, Tatsumi Y, Soyano F, Miyamatsu N, Sonoda N, Godai K, et al. Increase in homeostasis model assessment of insulin resistance (HOMA-IR) had a strong impact on the development of type 2 diabetes in Japanese individuals with impaired insulin secretion. the Saku study. PLoS ONE. 2014;9(9):e105827.
16. Huang F, Bai J, Zhang J, Yang D, Fan H, Huang L, et al. Identification of potential diagnostic biomarkers for pneumonia caused by adenovirus infection in children by screening serum exosomal microRNAs. Mol Med Rep. 2019;19(5):4306–14.
17. Chen Y, Wang Y, Jiang Y, Zhang X, Sheng M. High-glucose treatment regulates biological functions of human umbilical vein endothelial cells via Sirt1/FOXO3 pathway. Annals Transl Med. 2019;7(9):199.
18. Tripathi BK, Srivastava AK. Diabetes mellitus: complications and therapeutics. Medical science monitor. Diabet Mell. Compil Int Med. 2006;12(7):130–47.
19. Shen Y, Xu H, Pan X, Wu W, Wang H, Yan L, et al. miR-34a and miR-125b are upregulated in peripheral blood mononuclear cells from patients with type 2 diabetes mellitus. Exp Ther Med. 2017;14(6):5589–96.
20. Ye D, Zhang T, Lou G, Xu W, Dong F, Chen G, et al. Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients. Life Sci. 2018;208:201–7.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.